{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:01:51Z","timestamp":1787022111589,"version":"build-2736575974"},"reference-count":17,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T00:00:00Z","timestamp":1660780800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003653","name":"Korea National Institute of Health","doi-asserted-by":"crossref","award":["2019E520202"],"award-info":[{"award-number":["2019E520202"]}],"id":[{"id":"10.13039\/501100003653","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>In 2018, the World Health Organization recommended a 6-month four-drug regimen (rifampicin, ethambutol, pyrazinamide, and levofloxacin) for the treatment of isoniazid-monoresistant tuberculosis. However, the regimen had very low certainty. This cohort study assessed the impact of fluoroquinolone use and initial baseline regimen on treatment effectiveness in isoniazid-monoresistant tuberculosis. This multicenter retrospective cohort study included 318 patients with isoniazid-monoresistant tuberculosis notified between 2011 and 2018 in Korea. Baseline regimens were classified into two groups, namely 6\u20139-month rifampicin, ethambutol, and pyrazinamide (6-9REZ) and a combination regimen of 2-month rifampicin, ethambutol, pyrazinamide and 7\u201310-month rifampicin and ethambutol (2REZ\/7-10RE). Multivariable logistic regression was performed to assess factors associated with positive treatment outcomes. Of 318 enrolled patients, 234 (73.6%) were treated with the 6-9REZ and 103 (32.4%) with additional fluoroquinolone. In a multivariable logistic regression model comparing the 6-9REZ and 2REZ\/7-10RE groups, there was no difference in the odds of positive outcomes (adjusted odds ratio = 1.08, 95% confidence interval = 0.65\u20131.82). Addition use of fluoroquinolone was not associated with positive treatment outcomes in the whole cohort (adjusted odds ratio = 1.41, 95% confidence interval = 0.87\u20132.27); however, its additional use was beneficial in the 2REZ\/7-10RE subgroup (adjusted odds ratio = 3.58, 95% confidence interval = 1.32\u20139.75). Both initial baseline regimens, 6-9REZ and 2REZ\/7-10RE, were similarly effective. Shortening of the pyrazinamide administration duration with additional fluoroquinolone use could be a safe alternative for patients with potential hepatotoxicity related to pyrazinamide.<\/jats:p>","DOI":"10.1371\/journal.pone.0273263","type":"journal-article","created":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T13:42:56Z","timestamp":1660830176000},"page":"e0273263","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":8,"title":["Comparison of different regimens with or without fluoroquinolone in isoniazid-resistant tuberculosis: A multicenter cohort study"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6091-518X","authenticated-orcid":true,"given":"Jinsoo","family":"Min","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyung Woo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Young","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2226-8262","authenticated-orcid":true,"given":"Sung Kyoung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Woo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyoung Kyu","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Haak","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4433-231X","authenticated-orcid":true,"given":"Ju Sang","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,8,18]]},"reference":[{"key":"pone.0273263.ref001","doi-asserted-by":"crossref","first-page":"e1003008","DOI":"10.1371\/journal.pmed.1003008","article-title":"Prevalence and genetic profiles of isoniazid resistance in tuberculosis patients: A multicountry analysis of cross-sectional data","volume":"17","author":"AS Dean","year":"2020","journal-title":"PLOS Med"},{"key":"pone.0273263.ref002","doi-asserted-by":"crossref","first-page":"e1003023","DOI":"10.1371\/journal.pmed.1003023","article-title":"Isoniazid-resistant tuberculosis: A problem we can no longer ignore","volume":"17","author":"G Sulis","year":"2020","journal-title":"PLOS Med"},{"key":"pone.0273263.ref003","doi-asserted-by":"crossref","first-page":"129","DOI":"10.5588\/ijtld.16.0716","article-title":"Isoniazid-resistant tuberculosis: a cause for concern?","volume":"21","author":"HR Stagg","year":"2017","journal-title":"Int J Tuberc Lung Dis"},{"key":"pone.0273263.ref004","doi-asserted-by":"crossref","first-page":"20","DOI":"10.4046\/trd.2019.0065","article-title":"Treatment of isoniazid-resistant pulmonary tuberculosis","volume":"83","author":"BW Jhun","year":"2020","journal-title":"Tuberc Respir Dis (Seoul)"},{"key":"pone.0273263.ref005","volume-title":"WHO treatment guidelines for isoniazid-resistant tuberculosis: supplement to the WHO treatment guidelines for drug-resistant tuberculosis","author":"World Health Organization","year":"2018"},{"key":"pone.0273263.ref006","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1186\/s12879-020-05157-6","article-title":"Age-stratified anti-tuberculosis drug resistance profiles in South Korea: a multicenter retrospective study","volume":"20","author":"EG Lee","year":"2020","journal-title":"BMC Infect Dis"},{"key":"pone.0273263.ref007","doi-asserted-by":"crossref","first-page":"218","DOI":"10.4046\/trd.2020.0016","article-title":"Tuberculosis surveillance and monitoring under the National Public-Private Mix Tuberculosis Control Project in South Korea 2016\u20132017","volume":"83","author":"J Min","year":"2020","journal-title":"Tuberc Respir Dis"},{"key":"pone.0273263.ref008","doi-asserted-by":"crossref","first-page":"2100804","DOI":"10.1183\/13993003.00804-2021","article-title":"World Health Organization treatment outcome definitions for tuberculosis: 2021 update","volume":"58","author":"NN Linh","year":"2021","journal-title":"Eur Respir J"},{"key":"pone.0273263.ref009","doi-asserted-by":"crossref","first-page":"1900982","DOI":"10.1183\/13993003.00982-2019","article-title":"Fluoroquinolones and isoniazid-resistant tuberculosis: implications for the 2018 WHO guidance","volume":"54","author":"HR Stagg","year":"2019","journal-title":"Eur Respir J"},{"key":"pone.0273263.ref010","doi-asserted-by":"crossref","first-page":"290","DOI":"10.5588\/ijtld.15.0490","article-title":"Drug-resistant tuberculosis clinical trials: proposed core research definitions in adults","volume":"20","author":"J Furin","year":"2016","journal-title":"Int J Tuberc Lung Dis"},{"key":"pone.0273263.ref011","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.3349\/ymj.2020.61.12.1034","article-title":"Characteristics and treatment outcomes of isoniazid mono-resistant tuberculosis: A retrospective study","volume":"61","author":"SH Kwak","year":"2020","journal-title":"Yonsei Med J"},{"key":"pone.0273263.ref012","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S2213-2600(18)30078-X","article-title":"Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis","volume":"6","author":"F Fregonese","year":"2018","journal-title":"Lancet Respir Med"},{"key":"pone.0273263.ref013","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1164\/rccm.201909-1874ST","article-title":"Treatment of drug-resistant tuberculosis. An official ATS\/CDC\/ERS\/IDSA clinical practice guideline","volume":"200","author":"P Nahid","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"pone.0273263.ref014","unstructured":"Tuberculosis (NICE Guideline 33). National Institute for Health and Care Excellence; 2016."},{"key":"pone.0273263.ref015","doi-asserted-by":"crossref","first-page":"143","DOI":"10.4046\/trd.2018.0027","article-title":"Correlation between GenoType MTBDRplus assay and phenotypic susceptibility test for prothionamide in patients with genotypic isoniazid resistance","volume":"82","author":"JH Lee","year":"2019","journal-title":"Tuberc Respir Dis (Seoul)"},{"issue":"suppl_1","key":"pone.0273263.ref016","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofw172.422","article-title":"Treatment outcomes in low-level isoniazid resistant tuberculosis","volume":"3","author":"A Isaac","year":"2016","journal-title":"Open Forum Infect Dis"},{"key":"pone.0273263.ref017","doi-asserted-by":"crossref","first-page":"3620","DOI":"10.1128\/AAC.00077-13","article-title":"Epidemiology of isoniazid resistance mutations and their effect on tuberculosis treatment outcomes","volume":"57","author":"MN Huyen","year":"2013","journal-title":"Antimicrob Agents Chemother"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0273263","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T13:43:25Z","timestamp":1660830205000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0273263"}},"subtitle":[],"editor":[{"given":"Vipa","family":"Thanachartwet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,8,18]]},"references-count":17,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,8,18]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0273263","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,18]]}}}